Table of Contents

Invitation Letter .................................................................................................................. 3
About MDS .......................................................................................................................... 4
International Congress Information .................................................................................. 6
Congress Events .................................................................................................................. 8
CME Information ................................................................................................................ 9
Program at a Glance .......................................................................................................... 10
Session Definitions/Faculty Roles ....................................................................................... 11
Daily Schedule ................................................................................................................... 12
  Friday, October 5, 2018 ..................................................................................................... 12
  Saturday, October 6, 2018 ............................................................................................... 13
  Sunday, October 7, 2018 ................................................................................................. 16
  Monday, October 8, 2018 ............................................................................................... 19
  Tuesday, October 9, 2018 ............................................................................................... 22
Acknowledgements ............................................................................................................ 23
Membership Information .................................................................................................... 28
Dear Colleagues,

On behalf of the International Parkinson and Movement Disorder Society (MDS), we are pleased to formally invite you to attend the International Congress of Parkinson's Disease and Movement Disorders® in Hong Kong from October 5-9, 2018.

Hong Kong has a reputation of being a city of charm with a mix of tradition, cultural diversity and sophistication. It offers spectacular scenery and a skyline that has been regarded as the biggest visual impact of all world cities.

Each year, the International Congress attracts delegates from around the world who come to learn about the latest research and perspectives, to listen to world renowned speakers, and to be exposed to the most up-to-date information in the field of Movement Disorders. Once again, this year's International Congress promises to bring new ideas and unparalleled networking opportunities.

We look forward to welcoming you to Hong Kong and hope you will take advantage of the many exciting, educational opportunities the 2018 International Congress offers.

With kind regards,

Christopher Goetz
President, International Parkinson and Movement Disorder Society, 2017-2019

Buz Jinnah
Chair, Congress Scientific Program Committee, 2017-2019

Beomseok Jeon
Co-Chair, Congress Scientific Program Committee, 2018

Vincent Mok
Co-Chair, Congress Scientific Program Committee, 2018
About MDS

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

PURPOSE, MISSION AND GOALS

**Purpose:**
The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

**Mission and Goals:**
To disseminate knowledge about Movement Disorders by:
- Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
- Sponsoring International Congresses and Symposia on Movement Disorders
- Collaborating with other international organizations and lay groups
- Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of Movement Disorders by:
- Using the Society’s influence and resources to enhance support for research
- Facilitating the dissemination of information about research
- Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with Movement Disorders, the Society will provide expertise, advice and guidance to:
- Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
- The public (media) and patient support groups by informing them of new research and therapeutic advances
- Governments to assist them in the development of policies that affect support of research and patient care
- Educational efforts to assist in developing standards of training in the specialty

**MDS OFFICERS (2017-2019)**

President
Christopher Goetz, USA

President-Elect
Claudia Trenkwalder, Germany

Secretary
Susan Fox, Canada

Secretary-Elect
Bastiaan Bloem, Netherlands

Treasurer
Victor Fung, Australia

Treasurer-Elect
Louis Tan, Singapore

Past-President
Oscar Gershanik, Argentina
About MDS

MDS INTERNATIONAL EXECUTIVE COMMITTEE
Charles Adler, USA
Daniela Berg, Germany
Shengdi Chen, People’s Republic of China
Carlos Cosentino, Peru
Jeffrey Kordower, USA
Joaquim Ferreira, Portugal
D. James Surmeier, USA
Ryosuke Takahashi, Japan
Pille Taba, Estonia
Mayela Rodriguez Violante, Mexico

INTERNATIONAL CONGRESS OVERSIGHT COMMITTEE
Chair: Matthew Stern, USA
Gunther Deuschl, Germany
Victor Fung, Australia
Oscar Gershanik, Argentina
Christopher Goetz, USA
Beomseok Jeon, South Korea
Hyder Jinnah, USA
Vincent Mok, Hong Kong
Claudia Trenkwalder, Germany

CONGRESS LOCAL ORGANIZING COMMITTEE
Chair: Vincent CT Mok
Mandy Au Yeung
Anne Yin Yan Chan
Danny TM Chan
Germaine Hiu Fai Chan
Nelson Yuk-Fai Cheung
Ya Ke
Claire Ka Yee Lau
Michael WY Lee
Margaret KY Mak
Shirley YY Pang
Tak Lap Poon
Kin Lun Tsang
Jonas Yeung
Helen LK Yip
Ken KL Yung
Barong Zhang
Xian Lun Zhu

CONGRESS SCIENTIFIC PROGRAM COMMITTEE
Chair: Hyder Jinnah, USA
Co-Chair: Beomseok Jeon, South Korea
Co-Chair: Vincent Mok, Hong Kong
Roongroj Bhidayasiri, Thailand
Vincenzo Bonifaati, Netherlands
M. Angela Cenci Nilsson, Sweden
Shengdi Chen, People’s Republic of China
Jean-Christophe Corvol, France
Steven Frucht, USA
Emilia Gatto, Argentina
Christopher Goetz, USA
Jennifer Goldman, USA
Etienne Hirsch, France
Roland Dominic Jamora, Philippines
Han-Joon Kim, South Korea
Vladimir Kostic, Serbia
Shen-Yang Lim, Malaysia
Irene Litvan, USA
Karen Marder, USA
Wassilios Meissner, France
Elena Moro, France
Alice Nieuwboer, Belgium
Maria Stamelou, Greece
Matthew Stern, USA
Antonio Strafella, Canada
Carolyn Sue, Australia
Ryosuke Takahashi, Japan
Helio Teive, Brazil
Claudia Trenkwalder, Germany

PAST-PRESIDENTS
2015-2017: Oscar Gershanik, Argentina
2013-2015: Matthew Stern, USA
2011-2013: Gunther Deuschl, Germany
2009-2011: Philip Thompson, Australia
2007-2009: Anthony Lang, Canada
2005-2006: Andrew Lees, United Kingdom
2003-2004: C. Warren Olanow, USA
2001-2002: Werner Poewe, Austria
1999-2000: Mark Hallett, USA
1997-1998: Eduardo Tolosa, Spain
1995-1996: Joseph Jankovic, USA
1991-1994: C. David Marsden, United Kingdom
1988-1991: Stanley Fahn, USA

INTERNATIONAL MEDICAL SOCIETY FOR MOTOR DISTURBANCES PAST-PRESIDENTS
1993-1994: C. Warren Olanow, USA
1991-1992: Bastian Conrad, Germany
1989-1990: Mark Hallett, USA
1987-1988: Mario Manfredi, Italy
1985-1986: C. David Marsden, United Kingdom

MDS INTERNATIONAL SECRETARIAT
International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: info@movementdisorders.org
Website: www.movementdisorders.org

October 5-9, 2018 • HONG KONG • www.mdscongress.org
International Congress Information

Official Language
The official language of the 2018 International Congress is English.

Venue
Hong Kong Convention and Exhibition Centre
1 Expo Drive, Wan Chai
Hong Kong

Exhibition
Manufacturers, distributors and suppliers of products and services for physicians and researchers involved with Movement Disorders are invited to participate in the International Congress exhibition. To receive a copy of the Exhibitor Prospectus, please contact the MDS International Secretariat at congress@movementdisorders.org or visit the International Congress website at www.mdscongress.org/Congress-2018/Sponsor-Exhibit.htm. The exhibition is open to all registered delegates.

Abstract Poster Information
Poster Sessions will be featured Saturday through Monday during the International Congress to ensure delegates are given the opportunity to review as many abstracts as possible. Please visit www.mdscongress.org/Congress-2018/Abstracts.htm for a detailed poster schedule, including information about the Guided Poster Tours.

Fees (in USD):

<table>
<thead>
<tr>
<th></th>
<th>On or before August 2, 2018</th>
<th>From August 3 – September 5, 2018</th>
<th>From September 6 – October 9, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDS Member</td>
<td>$600</td>
<td>$650</td>
<td>$700</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$800</td>
<td>$850</td>
<td>$900</td>
</tr>
<tr>
<td>Junior Member/Participant*</td>
<td>$350</td>
<td>$375</td>
<td>$400</td>
</tr>
<tr>
<td>Health Professional (Non-Physician)</td>
<td>$350</td>
<td>$375</td>
<td>$400</td>
</tr>
</tbody>
</table>

The International Congress registration fee includes admission to all scientific sessions, Exhibit Hall and Poster Hall, a meeting bag and documentation. The registration fee excludes travel and accommodations.

*Junior Members of MDS, those born after January 1, 1988, residents, fellows and those still in training. Please fax or e-mail a copy of an official document indicating age or a letter from your employer stating training status to be eligible for this discount. Without documentation, the delegate will be charged the non-member rate (Fax: +1 514-289-9844 or e-mail: mdscongress@showcare.com within one week of submitting registration.)
International Congress Information

Registration Confirmation
Attendees who register online will receive a confirmation message immediately. Please present this confirmation at the International Congress registration desk in Hong Kong to receive your registration materials.

Cancellation/Refund Policy
All cancellations must be requested in writing.
• Up to September 5, 2018 (pre-registration deadline): 100% refund, minus a $75 administrative charge
• From September 6 – September 20, 2018: 50% refund
• From September 21, 2018 onward: no refund

Group Registration
Groups may be formed of six (6) or more delegates from the same company/travel agency.
Group leaders will be able to continually make changes to the group up until the final pre-registration deadline of September 5, 2018.

Registration Desk
Name badge, scientific session tickets, Final Program, USB with full abstract list, and International Congress bag can be collected at the International Congress Registration Hall 3 FG Foyer during the following hours**:
Friday, October 5 .............................................. 7:00 – 20:00
Saturday, October 6 ........................................... 7:00 – 18:00
Sunday, October 7 ............................................. 8:00 – 18:00
Monday, October 8 ............................................. 8:00 – 18:00
Tuesday, October 9 ............................................. 8:00 – 12:00
**Please note that these hours are subject to change. Please watch for updated schedules at www.mdscongress.org and look for the schedule in the Final Program.

Scientific Sessions
The 2018 Scientific Program will incorporate Therapeutic Plenary Sessions, Plenary and Parallel Sessions, Teaching Courses, Video Sessions, Skills Workshops, Guided Poster Tours and Blue Ribbon Highlights.

Sessions will focus on the latest developments in:
- Technology in the Diagnosis, Monitoring, and Management of Movement Disorders
- Movement Disorder topics, including, but not limited to, ataxia, chorea, dystonia, myoclonus, Parkinson’s disease, restless legs syndrome, spasticity, stereotypies, tics and tremors
- Basic Science issues, including, but not limited to, genetics, neuroimaging, neuropharmacology, surgical therapy and transplantation
- Other less common clinical conditions

Special Accessibility Needs
Delegates requiring special arrangements in order to fully participate in the International Congress should provide a written description of such needs on their registration form or send an e-mail to congress@movementdisorders.org. To ensure appropriate accommodations, all special needs should be addressed in advance with the MDS International Secretariat.

Photography Policy
Photography is not permitted in any of the 2018 International Congress scientific and/or educational sessions or in the poster areas.
International Congress Events

Friday, October 5, 2018
Welcome Ceremony
19:30 – 21:30

All International Congress attendees are warmly invited to attend the International Congress Welcome Ceremony. This event is open to all registered delegates.

Sunday, October 7, 2018
Young Delegates Reception
19:30 - 21:00

At the Renaissance Hong Kong Harbour View Hotel, Oasis Room

Join your colleagues at the Renaissance on Sunday evening for a networking event.

Monday, October 8, 2018
MDS Video Challenge
19:00 – 22:00

Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by the Panel of Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for attendees to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

The Panel of Experts are:
Bettina Balint, United Kingdom
Orlando Barsottini, Brazil
Sun Ju Chung, South Korea
Mark Edwards, United Kingdom
Roberto Erro, Italy

This event is open to all registered delegates. For more information about the MDS Video Challenge, please contact Sarah Smith at congress@movementdisorders.org.
CME Information

Target Audience
Clinicians, researchers, post-doctoral fellows, medical residents, medical students, allied health professionals with an interest in current clinical trends and approaches for diagnosis and treatment of movement disorders.

Objectives
1) Evaluate the pharmacological and non-pharmacological management options available for Parkinson’s disease and other movement disorders
2) Discuss the diagnostic approaches and tools available for Parkinson’s disease and other movement disorders
3) Describe the pathogenesis and neurobiology of Parkinson’s disease and other movement disorders

Satisfactory Completion
Participants must complete an evaluation to receive a certificate of continuing medical education credit. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco and International Parkinson and Movement Disorder Society. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement
Amedco designates this live activity for a maximum of 29.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
### International Congress Schedule-at-a-Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Friday, October 5</th>
<th>Saturday, October 6</th>
<th>Sunday, October 7</th>
<th>Monday, October 8</th>
<th>Tuesday, October 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Therapeutic Plenary Session 8:00 - 10:00</td>
<td>Plenary Session 8:00 - 9:30</td>
<td>Plenary Session 8:00 - 9:30</td>
<td>Plenary Session 8:00 - 9:30</td>
<td>Plenary Session 8:00 - 9:30</td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Regional Assemblies 10:00 - 11:00</td>
<td>Break 10:00 - 10:30</td>
<td>Plenary Session (Grand Rounds) 10:30 - 12:30</td>
<td>MDS Business Meeting 9:30 - 10:30</td>
<td>Break 9:30 - 10:00</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Controversies 10:00 - 11:00</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blue Ribbon Highlights 11:00 - 12:00</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Break 15:00 - 15:30</td>
<td>Break 15:00 - 15:30</td>
<td>Break 15:00 - 15:30</td>
<td>Break 14:45 - 15:00</td>
<td>Parallel Sessions/ Teaching Courses 15:00 - 17:00</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Break 16:30 - 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Break 17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Break 17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td>Skills Workshops/ Video Sessions 17:30 - 19:00</td>
</tr>
<tr>
<td>18:30</td>
<td>Break 17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>Break 17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td>Break 17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>Break 17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td>Break 17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td>Break 17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*International Congress of Parkinson's Disease and Movement Disorders® Preliminary Program*
International Congress Session Definitions

**Blue Ribbon Session:**
This session provides a critical review of the best poster presentations by a panel of experts, highlighting the relevance, novelty and quality of both clinical and basic research presented by the delegates.

**Controversies:**
This Plenary Session is designed to involve all International Congress attendees. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected “hot” topics will be open for debate among the panelists.

**Parallel Sessions:**
These concurrent sessions provide an in-depth report of the latest research findings, state-of-the-art treatment options, as well as a discussion of future strategies. Parallel sessions will have evidence-based components and incorporate the “hot” issues in Parkinson’s disease and other movement disorders.

**Plenary Sessions:**
These sessions provide a broad overview of the latest clinical and basic science research findings and state-of-the-art information.

**Skills Workshops:**
These clinic-based training sessions provide an educational illustration of clinical techniques and treatment procedures through demonstrations utilizing patient videotapes and proper equipment to further develop practitioners’ skills and knowledge within the field of treatment of movement disorders.

**Teaching Courses:**
These educational programs provide up-to-date information focused on a single topic. The sessions highlight both the clinical and basic science of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides. In addition, these programs provide ample time for questions and a discussion period at the conclusion of the presentations.

**Therapeutic Plenary Sessions:**
These sessions provide the latest information regarding the scientific and clinical evidence supporting treatment options for Parkinson’s disease and other movement disorders.

**Video Sessions:**
Designed to provide a broad overview of related movement disorders, the video sessions will focus on the phenomenology covering the many different kinds of movement disorders affecting the population today.

International Congress Non-CME Educational Sessions

**Corporate Therapeutic Symposia:**
These company-based informational sessions provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

**Guided Poster Tours:**
Guided Poster Tours give small groups of delegates an opportunity to hear discussion on a select group of abstracts in several sub-categories.

**MDS Video Challenge:**
The goal of this session is for attendees to learn from a series of unusual patients and observe how senior experts approach a challenging case. A world-renowned panel of Movement Disorders experts guide attendees through these unique Movement Disorder cases as they are presented by representatives from Movement Disorder Centers around the world.

**Poster Sessions:**
Poster sessions give each delegate an opportunity to view their colleagues’ posters on the most current research in the field of Movement Disorders. Authors are present for 90 minutes each day to explain their work and answer questions.

International Congress Faculty Roles

**Speaker / Presenter:** Creates and delivers the presentation materials, and participates in the dialogue of the session.

**Chair:** Facilitates the learnings of the session; ensures that learning objectives are met during the presentation(s), and engages the learners as needed.

**Liaison:** Develops the session from the onset and provides guidance to ensure that the overall objectives are met.

2018 International Congress Theme

At each annual International Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year’s theme, *Technology in the Diagnosis, Monitoring, and Management of Movement Disorders*, will be showcased in two Plenary Sessions, six Parallel Sessions, one Skills Workshop, one Teaching Course, and one Video Session. International experts will serve as faculty, and the meeting participants can elect to attend any or all of these sessions. Themed sessions are designated in the program with 🎓.
Friday, October 05, 2018

1101 Therapeutic Plenary Session
Update on Management Strategies for Parkinson’s Disease
8:00 – 10:00
Chairs: Shengdi Chen, People’s Republic of China
Alice Nieuwboer, Belgium

8:00 Early Pharmacologic Management
Olivier Rascol, France

8:40 Role of Rehabilitation and Exercise
Colleen Canning, Australia

9:20 Later Stage Parkinson’s Disease
Anthony Lang, Canada

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss management in early Parkinson’s disease including potential disease modifying strategies
2. Review current role of rehabilitation and exercise including physical, occupational and speech therapies
3. Describe management strategies for advanced Parkinson’s disease, including invasive interventions

1102 Therapeutic Plenary Session
Update on Management Strategies for Dystonia and Tremor
11:00 – 13:00
Chairs: Marina De Koning-Tijssen, Netherlands
Jonas Hon Ming Yeung, Hong Kong

11:00 Pharmacologic Management of Dystonia and Tremor: An Under-Utilized Approach?
Tiago Mestre, Canada

11:40 Botulinum Toxin for Dystonia and Tremor: Old Standards and New Opportunities
Raymond Rosales, Philippines

12:20 Surgical Intervention for Dystonia and Tremor: Past, Present and Future
Ritesh Ramdhani, USA

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe the differential diagnosis of tic disorders and new treatment approaches
2. Explain common and rare causes of myoclonus and options available for treatment
3. Outline the pathogenesis of restless legs syndrome and its evidenced based therapy

1103 Therapeutic Plenary Session
Update on Management Strategies of Hyperkinetic Movement Disorders: Tics, Myoclonus, and Restless Legs Syndrome
14:30 – 16:30
Chairs: Raymond Rosales, Philippines
Claudia Trenkwalder, Germany

14:30 Update on the Management Strategy of Tics: Differential Diagnosis and New Therapeutic Approaches
Andreas Hartmann, France

15:10 Update on the Management Strategy of Myoclonus: Common and Rare Causes and New Therapeutic Approaches
Marina De Koning-Tijssen, Netherlands

15:50 Update on Restless Legs Syndrome: Pathophysiological Concepts and Evidenced Based Therapy
Juliane Winkelmann, Germany

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Summarize the current state of the art in the treatment of movement disorders with DBS
2. Identify advantages and disadvantages of lesion-based therapies for movement disorders
3. Describe the most recent advances in DBS surgery for movement disorders

1104 Therapeutic Plenary Session
Update on Neurosurgical Management of Movement Disorders
17:00 – 19:00
Chairs: Günther Deuschl, Germany
Danny Chan, Hong Kong

17:00 Deep Brain Stimulation Surgery for Movement Disorders: Where Do We Stand
Patricia Limousin, United Kingdom

17:40 Current Role of Lesions in the Management of Movement Disorders
José Obeso, Spain

18:20 Current Trends and New Horizons in Neurosurgery for Movement Disorders
Andres Lozano, Canada

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Summarize the current state of the art in the treatment of movement disorders with DBS
2. Identify advantages and disadvantages of lesion-based therapies for movement disorders
3. Describe the most recent advances in DBS surgery for movement disorders
Saturday, October 06, 2018

2101 Plenary Session

Presidential Lectures
8:00 – 10:00
Chairs: Christopher Goetz, USA
Claudia Trempe, Germany
Marie Vitali, France
C. David Marsden Lecture Award Recipient
Eng-King Tan, Singapore
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2102 Themed Plenary Session

Modulation of Gene Expression and Neurodegenerative Movement Disorders
10:30 – 12:30
Chairs: Christine Klein, Germany
Baorong Zhang, People’s Republic of China
10:30 Overview of Epigenetics and Its Impact on Neurodegeneration
Tiago Outeiro, Germany
11:10 Overview of Non-Coding Genetic Elements and Their Impact on Neurodegeneration
Menno Creyghton, Netherlands
11:50 Therapeutic Implications of Epigenetic and Non-Coding Modulatory Elements
David Standaert, USA
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe the basic principles of epigenetics and their possible implications for neurodegeneration (including pathogenesis, biomarkers, and therapeutic targets)
2. Summarize current knowledge on the role of non-coding genetic sequences in the pathogenesis of Parkinson’s disease (cis-regulatory DNA elements, genetic enhancers, non-coding RNAs)
3. Discuss the therapeutic potential of manipulating epigenetic mechanisms and non-coding genetic elements for neurodegenerative diseases

2203 Parallel Session

Ethical Issues and Novel Technologies for the Practicing Clinician
15:30 – 17:30
Chairs: Beomseok Jeon, South Korea
Kapil Sethi, USA
15:30 Ethical Issues in Movement Disorders
Karen Romschfeldner, USA
16:10 Ethical Issues with Genetic Testing in the Next Generation Sequencing Era
Christine Klein, Germany
16:50 The Role of the Clinician In the Era of Advanced Diagnostic Testing
Beomseok Jeon, South Korea
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe the rationale and current status of immune therapies for Parkinson’s disease and other neurodegenerative disorders that involve abnormal protein accumulation
2. Describe the rationale and current status of novel genetic technologies for treatment of inherited neurological disorders
3. Describe the rationale and potential for modulating protein clearance mechanism such as autophagy for treatment of Parkinson’s disease and related disorders involving abnormal protein accumulation

2204 Parallel Session

Novel Technology-Based Therapies on the Horizon
15:30 – 17:30
Chairs: Olivier Rascal, France
David Standaert, USA
15:30 Active and Passive Immunization for Parkinson’s Disease and Other Proteinopathies
Werner Poewe, Austria
16:10 Gene Editing and Gene Silencing for Huntington’s Disease and Other Genetic Disorders
Dai Cleveland, USA
16:50 Enhancing Clearance of Pathological Proteins in Parkinson’s Disease and Other Proteinopathies
Seung-Jae Lee, South Korea
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Summarize different genes that are relevant in dystonia
2. Describe anatomical and pathological findings associated with dystonia
3. Identify physiological and network changes in the CNS associated with dystonia

2205 Parallel Session

New Insights in Dystonia: Genetics, Anatomy, and Neurophysiology
15:30 – 17:30
Chairs: Mark Hallett, USA
Hyder Jinnah, USA
15:30 Genetics
Katja Lohmann, Germany
16:10 Neuroanatomical Perspective
Ellen Hess, USA
16:50 Neurophysiology
Angelo Quaratanore, Italy
Recommended Audience: Basic scientists, Clinical academicians
At the conclusion of this session, participants should be better able to:
1. Summarize different genes that are relevant in dystonia
2. Describe anatomical and pathological findings associated with dystonia
3. Identify physiological and network changes in the CNS associated with dystonia
Saturday, October 06, 2018

2206 Parallel Session
What’s New in Genetics of Movement Disorders
15:30 – 17:30
Chairs: Nobutaka Hattori, Japan
Baorong Zhang, People’s Republic of China
15:30 Parkinson’s Disease and Parkinsonism
Vincenzo Bonifati, Netherlands
16:10 Hyperkinetic Movement Disorders
Carolyn Sue, Australia
16:50 Genetic Testing in the Next-Generation Sequencing Era
Martha Nance, USA

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Summarize recently identified genes related to Parkinson’s disease and Parkinsonism
2. Summarize recently identified genes related to dystonia, tremor paroxysmal movement disorders, and others
3. Discuss current genetic testing methods for the diagnosis of movement disorders

2207 Parallel Session
Evolution of Movement Disorders in the Pediatric Population
15:30 – 17:30
Chairs: Roland Dominic Jamora, Philippines
Yoshiko Nomura, Japan
15:30 A Practical Approach to the Diagnosis of Movement Disorders in Children
Yoshiko Nomura, Japan
16:10 The Spectrum of Childhood Movement Disorders and Their Evolution to Adulthood
Jennifer Friedman, USA
16:50 Crossing Barriers: Transitioning From Pediatric Care to Adult Care
Emmanuel Roze, France

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe a practical approach to the diagnosis of movement disorders in children
2. Recognize the spectrum of pediatric movement disorders and their evolution to adulthood
3. Describe the problems associated with transitioning from pediatric to adult neurology care

2208 Parallel Session
Late Breaking News in Movement Disorders
15:30 – 17:30
Chairs: Michael Okun, USA
Ryosuke Takahashi, Japan
15:30 IPS Cells: An Old and New Approach for Understanding and Treating Movement Disorders?
Ryosuke Takahashi, Japan
16:10 GBA Mutations: A Basis for Individualized Therapy in Parkinson’s Disease?
Nir Glad, Israel
16:50 Can Understanding LRRK2 Lead to New Therapies?
Chin-Hsiien Lin, Taiwan

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Explain the potential role of IPS cells for understanding and treating Parkinson’s disease
2. Identify recent progress in linking GBA mutations to disease mechanisms and their implication for treatment trials
3. Describe approaches for disease modifying therapy in PD with LRRK2 as target for therapeutic trials

2309 Teaching Course
Gait Abnormalities in Movement Disorders
15:30 – 17:30
Chairs: Bastiaan Bloem, Netherlands
Barry Snow, New Zealand
15:30 How to Examine Gait and Balance
John Nutt, USA
16:10 Gait Problems in Parkinsonism and Frontal Lobe Gait Disorders
Simon Lewis, Australia
16:50 Gait Problems in Hyperkinetic Movement Disorders
Bart Van De Warrenburg, Netherlands

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Identify new motion sensor systems for analysis, diagnosis, and assessment of tremor
2. Describe the advantages and disadvantages of technology-based assessments, and estimate its accuracy and test-re-test reliability
3. Integrate the classical criteria and new instruments for tremor characterization and assessment

2411 Skills Workshop
Traditional Methods vs. Novel Technologies for Assessing Tremor
18:00 – 19:30
Dietrich Haubenberger, USA
Fatta Nahab, USA

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Identify new motion sensor systems for analysis, diagnosis, and assessment of tremor
2. Describe the advantages and disadvantages of technology-based assessments, and estimate its accuracy and test-re-test reliability
3. Integrate the classical criteria and new instruments for tremor characterization and assessment
Saturday, October 06, 2018

**2412 Skills Workshop**

**Practical Use of the MDS-UPDRS: A Global Effort**

18:00 – 19:30

Vincent Mok, Hong Kong

Glenn Stebbins, USA

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Apply and interpret the scale in clinical and research settings including available technological advances including apps and on-line training program
2. Practice using the MDS-UPDRS through interactive exercises and test cases during the session
3. Recognize the process utilized to develop non-English official versions of the MDS-UPDRS with special emphasis on available Asian language editions

**2413 Skills Workshop**

**Integrative Medicine and Multidisciplinary Care**

18:00 – 19:30

Jennifer Goldman, USA

Alice Nieuwboer, Belgium

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Identify the value and efficacy of integrated care management for different stages of Parkinson's disease and other common movement disorders
2. Appraise the scientific basis of non-pharmacological interventions of Parkinson's disease and other common movement disorders
3. Optimize strategies and logistics to implement patient-centered care in movement disorder clinics

**2414 Skills Workshop**

**Novel Scientific Tools For Advancing the Understanding of Movement Disorders**

18:00 – 19:30

Tomas Bjorklund, Sweden

Alexandra Nelson, USA

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe possible applications of optogenetics and chemogenetics to study the pathophysiology of movement disorders
2. Define the basic principles of CRISPR/Cas9 methodology for editing genomic DNA
3. Describe the technical and biological requirements that need to be fulfilled for a fruitful application of the above technologies

**2515 Video Session**

**Showcases From Asia**

18:00 – 19:30

Cid Czarina Diesta, Philippines

Shen-Yang Lim, Malaysia

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize hereditary movement disorders which are more common in Asians
2. Recognize acquired movement disorders which are related with environment or culture in Asians
3. Discuss how geographical origin or ethnic background can influence differential diagnosis

**2516 Video Session**

**Unusual Movement Disorders**

18:00 – 19:30

Carlos Cosentino, Peru

Francesca Morgante, Italy

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize less common inherited movement disorders
2. Recognize less common acquired or idiopathic movement disorders
3. Describe an approach to the differential diagnosis of unusual movement disorders

**2517 Video Session**

**How to Examine: A Clinician’s Perspective of Bedside Examination**

18:00 – 19:30

Niall Quinn, United Kingdom

Stephen Reich, USA

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe optimal techniques to elicit a comprehensive history
2. Develop best techniques to elicit an informative examination
3. Develop appropriate reasoning to achieve accurate diagnoses

**2518 Video Session**

**Ataxia**

18:00 – 19:30

Orlando Barsottini, Brazil

Kinya Ishikawa, Japan

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Identify clinical features in the differential diagnosis of acquired, sporadic, and hereditary ataxias
2. Review the systematic work up of the ataxias
3. Discuss examination strategies to elicit and facilitate the diagnosis of ataxia signs and symptoms
## Sunday, October 07, 2018

### 3101 Plenary Session

#### Update on Recent Clinical Trials
**8:00 – 9:30**

**Chairs:** Carolyn Sue, Australia  
Louis Tan, Singapore  

8:00 | Update on Clinical Trials in Parkinson's Disease: Motor  
Thomas Foltynek, United Kingdom  

8:30 | Update on Clinical Trials in Parkinson's Disease: Non-Motor  
Karen Marder, USA  

9:00 | Update on Clinical Trials in Atypical Parkinsonian Disorders  
Wassilios Meissner, France  

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees  

At the conclusion of this session, participants should be better able to:  
1. Discuss recent clinical trials in Parkinson's disease  
2. Review recent clinical trials for non-motor features of Parkinson's disease  
3. Discuss recent clinical trials for atypical parkinsonian disorders

### 3102 Plenary Session

#### Grand Rounds
**10:30 – 12:30**

**Chairs:** Mandy Au Yeung, Hong Kong  
Yuk-Fai Nelson Cheung, Hong Kong  
Vincent Mok, Hong Kong  

MDS Experts: Kailash Bhatia, United Kingdom  
Susan Fox, Canada  
Yoshikuni Mizuno, Japan  
Mayela Rodriguez Violante, Mexico  

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees  

At the conclusion of this session, participants should be better able to:  
1. Identify how experts use the clinical history and exam to formulate their diagnosis in movement disorders cases  
2. Identify how experts use diagnostic testing in the differential diagnosis of movement disorders  
3. Identify how experts plan therapies for movement disorder patients

### 3203 Parallel Session

#### Advances in Stem Cells and Parkinson’s Disease
**15:30 – 17:30**

**Chairs:** Dimitri Kainc, USA  
Ken Yung, Hong Kong  

15:30 | Human Stem Cells: Options Available  
Jeffrey Kordower, USA  

16:10 | Modeling Pathogenesis of Parkinson’s Disease  
Dimitri Kainc, USA  

16:50 | Stem Cells for Therapeutics: Fantasy or Reality?  
Anne Rosen, United Kingdom  

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees  

At the conclusion of this session, participants should be better able to:  
1. Describe the history and technological advances in stem cell biology  
2. Explain how stem cells can be used to study the pathogenesis of Parkinson's disease  
3. Discuss the current status of stem cell therapy including challenges and pitfalls

### 3204 Parallel Session

#### Technologies to Advance Neuromodulation Therapy for Movement Disorders
**15:30 – 17:30**

**Chairs:** Volker Goenen, Germany  
Takami Tan, Japan  

15:30 | New Engineering Technologies  
Alberto Priori, Italy  

16:10 | New Surgical Strategies  
Volker Goenen, Germany  

16:50 | New Technologies for Patient Selection  
Maria Cantarino, Netherlands  

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees  

At the conclusion of this session, participants should be better able to:  
1. Describe the most recent advances in neuromodulation technologies including closed loop and adaptive stimulation and steerable electrodes  
2. Compare emerging trends in surgical strategies including intraoperative imaging, local field potentials, or networks

### 3205 Parallel Session

#### Visual Hallucinations in Parkinson’s Disease and Lewy Body Dementias: From Mechanism to Management
**15:30 – 17:30**

**Chairs:** Jennifer Goldman, USA  
Daniel Weintraub, USA  

15:30 | Current Theories on Visual Hallucinations  
John-Paul Taylor, United Kingdom  

16:10 | Neuroimaging and Visual Hallucinations: A Window Into Their Mechanism  
Javier Pagonabarraga, Spain  

16:50 | Management Strategies for Visual Hallucinations  
Daniel Weintraub, USA  

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees  

At the conclusion of this session, participants should be better able to:  
1. Discuss current theories of visual hallucinations in Parkinson’s disease and Lewy body dementias  
2. Describe neuroimaging findings associated with visual hallucinations in Parkinson’s disease and Lewy body dementias  
3. Review management strategies for visual hallucinations in Parkinson’s disease and Lewy body dementias
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Title</th>
<th>Chairs</th>
<th>Time</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>3208</td>
<td>Parallel Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3208</td>
<td>Parallel Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3206</td>
<td>Parallel Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3206</td>
<td>Parallel Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3207</td>
<td>Parallel Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3207</td>
<td>Parallel Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3308</td>
<td>Parallel Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3308</td>
<td>Parallel Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3309</td>
<td>Teaching Course</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3309</td>
<td>Teaching Course</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3310</td>
<td>Teaching Course</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3310</td>
<td>Teaching Course</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sunday, October 07, 2018**

**3206  Parallel Session**

**Prodromal Parkinson’s Disease**

**15:30 – 17:30**

**Chairs:**
- Daniela Berg, Germany
- Etienne Hirsch, France

**15:30**
- Clinical, Genetic, and Imaging Features
  - Daniela Berg, Germany

**16:10**
- Understanding the Biological Basis of Prodromal Parkinson’s Disease
  - Etienne Hirsch, France

**16:50**
- The Future: How to Modify the Course of Parkinson’s Disease
  - Jean-Christophe Corvol, France

**Recommended Audience:**
- Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Identify clinical genetic and imaging features for prodromal Parkinson’s disease
2. Explain the pathophysiological basis for prodromal Parkinson’s disease
3. Discuss future clinical trial design and strategies for disease modification

**3207  Parallel Session**

**Challenges in Clinicogenetic Correlations: One Gene – Many Phenotypes; One Phenotype – Many Genes**

**15:30 – 17:30**

**Chairs:**
- Vincenzo Bonifati, Netherlands
- Hyder Jinnah, USA

**15:30**
- One Gene – Many Phenotypes
  - Roberto Erro, Italy

**16:10**
- One Phenotype – Many Genes
  - Marialuisa Quadri, Netherlands

**16:50**
- Clinical Implications – Diagnosis and Management Strategies
  - Eng King Tan, Singapore

**Recommended Audience:**
- Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize the sometimes different and complex phenotypes of monogenic mutations
2. Recognize similar clinical phenotypes resulting from different genetic mutations
3. Discuss the evolving role of genetics in the diagnosis and management of movement disorders

**3208  Parallel Session**

**Understanding and Managing Complex Gait Disorders in Parkinson’s Disease**

**15:30 – 17:30**

**Chairs:**
- Nir Glid, Israel
- Alice Nieuwboor, Belgium

**15:30**
- The Interplay Between Walking Ability and Cognitive Function
  - Lynn Rochester, United Kingdom

**16:10**
- Complex Gait and Postural Instability: A Balancing Act?
  - Colum MacKinnon, USA

**16:50**
- Assessment and Therapeutic Options for Complex Gait Disorders: A Contemporary View
  - Bastiaan Bloem, Netherlands

**Recommended Audience:**
- Basic scientists, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Identify how prefrontal dysfunction impacts on complex walking ability
2. Identify the locomotor-brainstem network abnormalities underlying gait disorders
3. Discuss management strategies which target the complexity of gait deficits

**3309  Teaching Course**

**Wearable Technology and Machine Learning for Quantitative Evaluation of Parkinson’s Disease**

**15:30 – 17:30**

**Chairs:**
- Roongroj Bhidayasiri, Thailand
- Alberto Espay, USA

**15:30**
- Wearable Sensors and Smart Phones: Can They Be Diagnostic Tools?
  - Alberto Espay, USA

**16:10**
- Machine Learning and Large-Scale Sensor-Based Analysis for Parkinson’s Disease
  - Bjorn Eskofier, Germany

**16:50**
- Wearable Technology for Monitoring Patients at Home
  - Roongroj Bhidayasiri, Thailand

**Recommended Audience:**
- Basic scientists, Clinical academicians, Non-physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize the clinical features of Huntington’s disease subtypes and generate a classification-oriented differential diagnosis
2. Discuss disease mechanisms and genetic modifiers for Huntington’s disease
3. Describe symptomatic therapies for chorea and emerging strategies to address Huntington’s disease progression

**3310  Teaching Course**

**Update on Huntington’s Disease and Other Choreas**

**15:30 – 17:30**

**Chairs:**
- Emilia Gatto, Argentina
- Hui Fang Shang, People’s Republic of China

**15:30**
- Huntington’s Disease Clinical Recognition and Differential Diagnosis of Chorea
  - Hui Fang Shang, People’s Republic of China

**16:10**
- Current Concepts of Huntington’s Disease Pathogenesis
  - Alexandra Durr, France

**16:50**
- Symptomatic and Disease Modifying Treatments for Chorea and Huntington’s Disease
  - Hitoshi Okazawa, Japan

**Recommended Audience:**
- Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe novel technologies that may be applied to diagnosis of movement disorders
2. Discuss the future use of wearable technology and web-based applications
3. Explain machine learning approaches for large data analyses
### Sunday, October 07, 2018

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3411</strong></td>
<td>Skills Workshop</td>
<td>18:00 – 19:30</td>
<td>Onanong Jitkritsadakul, Thailand; Jalesh Panicker, United Kingdom</td>
</tr>
<tr>
<td><strong>3412</strong></td>
<td>Atypical Parkinson Disorders: Multiple System Atrophy and Corticobasal Degeneration / Progressive Supranuclear Palsy</td>
<td>18:00 – 19:30</td>
<td>Han-Joon Kim, South Korea; Maria Stamelou, Greece</td>
</tr>
<tr>
<td><strong>3413</strong></td>
<td>Botulinum Toxins</td>
<td>18:00 – 19:30</td>
<td>Ryuji Kaji, Japan; Erle Chuen-Hian Lim, Singapore</td>
</tr>
<tr>
<td><strong>3414</strong></td>
<td>Lessons from My Patients</td>
<td>18:00 – 19:30</td>
<td>Cynthia Comella, USA; Oscar Gershon, Argentina; Philip Thompson, Australia</td>
</tr>
<tr>
<td><strong>3415</strong></td>
<td>Rare Autoimmune and Infectious Movement Disorders Not to Miss</td>
<td>18:00 – 19:30</td>
<td>Bettina Balint, United Kingdom; Mohit Bhatt, India</td>
</tr>
<tr>
<td><strong>3416</strong></td>
<td>Tremor Update</td>
<td>18:00 – 19:30</td>
<td>Günther Deuschl, Germany; Rodger Elble, USA</td>
</tr>
<tr>
<td><strong>3417</strong></td>
<td>Challenges in Movement Disorders Education: A Comparison of Africa and Asia</td>
<td>18:00 – 19:30</td>
<td>Njideka Okubadejo, Nigeria; Louis Tan, Singapore</td>
</tr>
<tr>
<td><strong>3418</strong></td>
<td>Eye Movements</td>
<td>18:00 – 19:30</td>
<td>Ji-Soo Kim, South Korea; Aasef Shaikh, USA</td>
</tr>
</tbody>
</table>

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of each session, participants should be better able to:
1. **Identify the basis of bladder and sexual dysfunction in Parkinson’s disease**
2. **Recognize the impact of bladder and sexual dysfunction on quality of life for patient and partner**
3. **Determine evidence-based and state-of-the-art management strategies for bladder and sexual dysfunction in Parkinson’s disease**

1. **Summarize the history and evolution of the term “essential tremor”**
2. **Describe more challenging cases and how to deal with them**
3. **Outline areas of ongoing uncertainty in the differential diagnosis of various tremors**

1. **Recognize characteristic eye movement abnormalities**
2. **Describe the recently proposed changes in the definitions and classifications of all tremors**
Monday, October 08, 2018

4101 Plenary Session
Advances in Huntington's Disease
8:00 – 9:30
Chairs: Karen Marder, USA
Hitoshi Okazawa, Japan
8:00 Novel Diagnostic Criteria for Huntington's Disease
Christopher Ross, USA
8:30 Clinical, Brain Imaging, and Wet Biomarkers for Monitoring of Huntington's Disease
Progression
Emilia Gatto, Argentina
9:00 From Bench to Bedside: New Therapeutic Approaches for Huntington's Disease
Beverly Davidson, USA
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe novel diagnostic criteria for Huntington's disease
2. Identify clinical, brain imaging, and biomarkers for the diagnosis of Huntington's disease and to monitor disease progression
3. Discuss new therapeutic approaches in Huntington's disease

4203 Parallel Session
New Imaging Frontiers in Movement Disorders
15:00 – 17:00
Chairs: Stephane Lehericy, France
Antonio Sfradella, Canada
15:00 MRI, Ultra-High Field and Iron Imaging
Stephane Lehericy, France
15:40 Imaging Neurotransmitter Receptors
Maria Cecilia Peralta, Argentina
16:20 New Frontiers in Molecular Imaging
Makoto Higuchi, Japan
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Explain existing and emerging MRI-based methods in the diagnosis or monitoring of movement disorders
2. Describe the role of neurotransmitter-based imaging methods in the diagnosis or monitoring of movement disorders
3. Summarize novel imaging-based methods in the diagnosis or monitoring of movement disorders

4102 Plenary Session
Technology Based Assessments in Movement Disorders: Assessing Health and Treatment Response
10:00 – 12:00
Chairs: Rodger Elble, USA
Alberto Espay, USA
10:00 Biometric Monitoring Devices: Assessing Health, Disease Progression and Treatment Response
Walter Maetzler, Germany
10:40 Technology Based Assessment of Disability and Treatment Response in Premanifest and Manifest Huntington's Disease
Ralf Reilmann, Germany
11:20 Technology Based Assessments to Enhance Remote Monitoring in Parkinson’s Disease
Anat Mirelman, Israel

4204 Parallel Session
Special Topics in Movement Disorders
15:00 – 17:00
Chairs: Steven Frucht, USA
Rachel Saunders-Pullman, USA
15:00 Gender Differences
Rachel Saunders-Pullman, USA
15:40 Regional, Racial and Ethnic Differences
Roland Dominic Jamora, Philippines
16:20 In-Hospital Consultations
Tim Anderson, New Zealand
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe the epidemiology and risk factors for movement disorders in men and women
2. Relate genetic and environmental risk factors to differences in prevalence and incidence of movement disorders
3. Define the diagnosis and treatment of emergency room and intensive care movement disorder consultations

4205 Parallel Session
Complementary and Alternative Medicine in Parkinson's Disease
15:00 – 17:00
Chairs: Benzi Kluger, USA
Vincent Mok, Hong Kong
15:00 Eastern Perspective
Sujith Ovalleth, India
15:40 Western Perspective
Benzi Kluger, USA
16:20 Why Are Patients with Parkinson's Disease Attracted to CAM?
Sun Ju Chung, South Korea
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Summarize the epidemiology and scientific evidence of CAM in Parkinson's disease including acupuncture, Chinese Herbs, Ayurvedic Medicine
2. Describe evidence both for and against western CAM in Parkinson's disease including marijuana and mucuna supplements
3. Summarize the human factors, mass media effects, and our recommendation for complementary alternative medicine to patients with Parkinson's disease
Monday, October 08, 2018

4206 Parallel Session
Tardive Syndromes: A Re-Emerging Crisis?
15:00 – 17:00
Chairs: Cynthia Comella, USA
Vladimir Kostic, Serbia
15:00 Tardive Syndromes: Causes, Incidence and Prevalence of a Re-emerging Crisis
Caroline Tannese, USA
15:40 The Broad Phenotype of Tardive Syndromes: Challenges for Recognition
Vladimir Kostic, Serbia
16:20 Management Challenges in Tardive Syndromes: New Opportunities?
Pierre Blanchet, Canada
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize the causes, incidence and prevalence of tardive syndromes
2. Recognize usual and unusual tardive syndromes, and differentiate them from their mimics
3. Formulate a treatment paradigm for patients with tardive syndromes

4207 Parallel Session
The Microbiome-Gut-Brain Axis and Parkinson’s Disease
15:00 – 17:00
Chairs: Yuk Fai Cheung, Hong Kong
Shen-Yang Lim, Malaysia
15:00 Basic Concepts of the Microbiome and Its Impact on Human Health and Disease
Filip Scheperejans, Finland
15:40 The Microbiome in Parkinson’s Disease and Multiple System Atrophy: Clinical Studies
Al Huey Tan, Malaysia
16:20 The Microbiome and Parkinson’s Disease: Basic Studies
Ali Keshavarzian, USA
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe non-dopaminergic lesions in Parkinson disease and their related symptoms
2. Summarize what has been learned from animal models of Lewy and tau pathology
3. Describe the role of a-synuclein and tau in pathology spreading

4208 Parallel Session
Fatal Attraction Between Tau and Alpha Synuclein in Parkinson’s Disease Pathology
15:00 – 17:00
Chairs: Glenda Halliday, Australia
Günter Höglinger, Germany
15:00 Neuropathological Findings
Glenda Halliday, Australia
15:40 What Can We Learn from Animal Models?
Günter Höglinger, Germany
16:20 Biochemical and Molecular Mechanisms
Ronald Melki, France
Recommended Audience: Basic scientists, Clinical academicians, Students/Residents/Trainees Description

At the conclusion of this session, participants should be better able to:
1. Describe non-dopaminergic lesions in Parkinson disease and their related symptoms
2. Summarize what has been learned from animal models of Lewy and tau pathology
3. Describe the role of a-synuclein and tau in pathology spreading

4309 Teaching Course
Treatable Movement Disorders Not to Miss
15:00 – 17:00
Chairs: Ryuji Kaji, Japan
Yih-Ru Wu, Taiwan
15:00 Treatable Early-Onset Disorders with Chorea and Dystonia
Ruth Walker, USA
15:40 Treatable Early-Onset Disorders with Ataxia and Spasticity
Hélio Teive, Brazil
16:20 Treatable Early-Onset Disorders with Parkinsonism
Yih-Ru Wu, Taiwan
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize, diagnose and treat juvenile chorea and dystonia
2. Describe and differentiate juvenile ataxia and spasticity, including management options
3. Discuss the diagnosis and management of Parkinsonism in young patients
Monday, October 08, 2018

4411  Skills Workshop
Atypical Presentations of Common Movement Disorders
17:30 – 19:00
Barry Snow, New Zealand
Pille Taba, Estonia
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Describe the various clinical presentations of Parkinson’s disease and other parkinsonian syndromes
2. Describe the sometimes unusual presentations of other movement disorders
3. Describe atypical presentations of well-known genetic disorders

4412  Skills Workshop
How to Become a Successful Movement Disorder Specialist
17:30 – 19:00
Shengdi Chen, People’s Republic of China
Esther Cubo, Spain
Stanley Fahn, USA
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize the best approaches to become an excellent movement disorder specialist
2. Describe the best approaches to succeed in academia and practice
3. Identify essential aspects of becoming an effective leader

4413  Skills Workshop
Speech Analysis and Therapy
17:30 – 19:00
Hanneke Kalf, Netherlands
Serge Pinto, France
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Examine speech and voice related symptoms of movement disorders
2. Describe current and emerging technologies for speech/swallowing evaluation
3. Summarize treatment strategies that may be applied for different speech disorders

4414  Skills Workshop
Spasticity Update
17:30 – 19:00
David Simpson, USA
Giovanni Stevanin, France
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize the varied clinical manifestations of different spasticity disorders, hereditary and acquired
2. Describe the biological mechanisms that may cause spasticity
3. Summarize current and emerging treatments for different types of spasticity

4515  Video Session
Practical Strategies for Tai Chi and Other Exercise Therapies for Parkinson’s Disease
17:30 – 19:00
Madeleine Hackney, USA
Margaret Mak, Hong Kong
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize the breadth of exercise and Tai Chi options in managing Parkinson’s disease
2. Appraise the evidence on the efficacy and dosing of exercise and Tai Chi for Parkinson’s disease
3. Formulate strategies for integrating exercise and Tai Chi into the comprehensive management of people with Parkinson’s disease

4516  Video Session
Movement Disorder Emergencies
17:30 – 19:00
Mandy Au-Yeung, Hong Kong
Steven Frucht, USA
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize clinical settings and signs in movement disorder emergencies
2. Outline management strategies of Parkinson-related emergencies
3. Outline management strategies of common non-Parkinsonian emergencies

4517  Video Session
Psychogenic Movement Disorders
17:30 – 19:00
Kathrin LaFaver, USA
Jon Stone, United Kingdom
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize in a patterned approach the clinical profiles of hyperkinetic psychogenic movement disorders
2. Describe the clinical characteristics of psychogenic Parkinsonism and other hypokinetic psychogenic movement disorders
3. Identify the common social, psychological, medical, and legal circumstances associated with psychogenic movement disorders

4518  Video Session
Challenging Cases in DBS
17:30 – 19:00
Anna Castrioto, France
Riaan Van Coller, South Africa
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
At the conclusion of this session, participants should be better able to:
1. Recognize common and uncommon challenges in managing DBS patients with movement disorders
2. Identify diagnostic clues and treatment options in difficult DBS cases
3. Apply available strategies in managing challenging DBS cases
### 5101 Plenary Session
#### Biomarkers for Parkinson's Disease
**8:00 – 9:30**

**Chairs:** Oscar Gershanik, Argentina  
Shu-Leong Ho, Hong Kong

- **8:00** What Makes a Good Biomarker?  
  Brit Mollenhauer, Germany
- **8:30** Body Fluid and Tissue Biomarkers: Current and Future  
  Douglas Galasko, USA
- **9:00** Imaging Biomarkers: Current and Future  
  Antonio Strafella, Canada

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Define the characteristics of a good biomarker for Parkinson's disease
2. Describe proposed body fluid and tissue biomarkers for predicting or monitoring clinical features of Parkinson's disease
3. Summarize the role of neuroimaging for predicting or monitoring clinical features of Parkinson's disease

### 5102 Plenary Session
#### Controversies in Movement Disorders
**10:00 – 11:00**

**Chairs:** Anthony Lang, Canada  
Philip Thompson, Australia

- **10:00** Is DBS Superior to Lesioning in Movement Disorders Therapy? (YES)  
  Elena Moro, France
- **10:15** Is DBS Superior to Lesioning in Movement Disorders Therapy? (NO)  
  Takaomi Taira, Japan
- **10:30** Does Parkinson's Disease Start in the Gut? (YES)  
  Kathleen Shannon, USA
- **10:45** Does Parkinson's Disease Start in the Gut? (NO)  
  Roberto Cilia, Italy

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe the advantages and disadvantages of different surgical therapies for movement disorders
2. Explain “gut-brain axis” proposed by Braak and the evidence supporting or refuting

### 5103 Plenary Session
#### Blue Ribbon Highlights
**11:00 – 12:00**

**Angela Cenci,** Sweden  
**Un Kang,** USA

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

This session will provide a critical review of the best poster presentations by a panel of experts, highlighting the relevance, novelty, and quality of both clinical and basic research presented by delegates.

At the conclusion of this session, participants should be better able to:
1. Review recent developments in the basic sciences of Movement Disorders
2. Review recent developments in clinical diagnosis or monitoring of Movement Disorders
3. Explain how recent developments may impact our treatment of Movement Disorders
Acknowledgements

The International Congress of Parkinson’s Disease and Movement Disorders wishes to acknowledge the following commercial supporters:

Platinum Level

AbbVie

ACORA

Bial

Biogen

Boston Scientific

Britannia Pharmaceuticals Ltd

GE Healthcare

Medtronic

Sunovion

Gold

Abbott

Zambon

Above companies are confirmed as of May 9, 2018
Acorda Therapeutics is committed to improving the lives of people with Parkinson’s. We are proud to be a platinum sponsor at the 22nd International Congress of Parkinson’s Disease and Movement Disorders.
STIMVIEW™ Technology makes directional programming intuitive and simple.*

*One click buttons make directional programming intuitive and simple.

Product available in the European Economic Area (EEA) only. Please check availability with your local sales representative or customer service.

Boston Scientific is a Global Company. Vercise Gevix is not currently licensed in accordance with Canadian Law.

LIRCA 2150 61217

Vercise DBS: Lead-only system (before stimulator is implanted) is MR conditional. An MRI examination can be conducted safely when all instructions in the supplemental manual ImageReady™ MRI Guidelines for Boston Scientific DBS Systems are followed.

The Vercise™ PC Deep Brain Stimulation (DBS) System is indicated for use in unilateral or bilateral stimulation of the subthalamic nucleus (STN) or internal globus pallidus (GPI) for treatment of levodopa-responsive Parkinson’s disease which is not adequately controlled with medication and also for treatment of intractable primary and secondary dystonia, for persons 7 years of age and older.

Thalamic stimulation using the Boston Scientific Vercise™ PC DBS System is indicated for the suppression of tremor not adequately controlled by medications in patients diagnosed with Essential Tremor or Parkinson’s disease.

All cited trademarks are the property of their respective owners. CAUTION: The laws restrict these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations.

Not for distribution in France.

NM-383421-AB_JUN2017 © 2017 Boston Scientific Corporation or its affiliates. All rights reserved.
A VIEW INTO PARKINSON’S

VISIT THE
SUNOVION BOOTH

Join us for an immersive and interactive exhibit that illustrates life with Parkinson’s disease and the types of OFF episodes that patients experience.

LEARN MORE about the struggles of Maggie*, a patient with moderate-to-advanced Parkinson’s disease, and the Little Big Things™ that may improve her daily life.

*Fictional patient for illustration only.
PARTNERSHIP AT EVERY STEP FOR DBS PATIENTS

Together, we are improving DBS patient lives at every step. We support you and your patients along the care continuum with our solutions and services.

To learn more, come see us at the booth.

Medtronic.com

This therapy is not for everyone. DBS Therapy requires brain surgery which could have serious or even fatal complications. Other complications can occur and may require additional surgery. Medtronic DBS Therapy may cause worsening of some symptoms. For additional safety information, please refer to indications, Safety and Warnings at Medtronic.com.

© 2018 Medtronic. UC201811972a EN
Become a Member of MDS

Meet & collaborate with over 7,000 colleagues across the globe and become a part of a Medical and Educational community dedicated to disseminating knowledge and promoting research to advance the field of Movement Disorders.

**MDS Members receive the following benefits:**
- **Peer Reviewed Journals:** Movement Disorders and Movement Disorders – Clinical Practice
- **Quarterly Newsletter:** Moving Along
- **Reduced Course Registration Rates**
- **Online Resources:** CME Activities; Streaming Content; Training Videos; and a Video Library with over 1,800 searchable videos

**NON-MEMBER OPPORTUNITIES**
- Free One-Year Trial Membership
- Open to Eligible International Congress Delegates

**ASSOCIATE MEMBERSHIP**
Non-members attending the International Congress have the opportunity to receive membership with MDS absolutely free for a year. Eligible participants will be invited by e-mail to apply for free Associate Membership. Interested individuals are encouraged to apply online within 30 days of contact.

Learn more at www.movementdisorders.org/associate-membership.htm or contact the International Secretariat:

MDS International Secretariat
555 East Wells Street, Suite 1100
Milwaukee, WI 53202 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: info@movementdisorders.org
2018 Important Dates

August 2, 2018
Early Registration Deadline

September 5, 2018
Final Pre-Registration Deadline

October 5-9, 2018
International Congress of Parkinson’s Disease and Movement Disorders®

Save The Date:
International Congress of Parkinson’s Disease and Movement Disorders®
Nice, France
September 22-26, 2019

International Parkinson and Movement Disorder Society